Akcea Therapeutics (NASDAQ: AKCA) has promoted Kyle Jenne to chief commercial officer. Jenne joined Boston-based Akea in 2017 as US commercial head. His appointment comes month after a corporate shakeup that led to the departure of three executives. Akcea is working to commercialize inotersen (Tegsedi), a drug approved by the FDA last year as a treatment for the nerves damage caused by the rare disease hereditary transthyretin amyloidosis.
Sponsored · Whitepaper
What the most successful life sciences fundraising pitch decks all have in common
Brex
Xconomy Insight · Special Report
Industry experts explain what it takes to launch a new biotech company
Sponsored · Whitepaper
A Guide to Performing Check-ups on Pharmaceutical Distribution & Patient Access Programs
Archbow Consulting
